These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1193 related articles for article (PubMed ID: 23633553)

  • 41. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C; Haahr T; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The effectiveness and safety of in vitro maturation of oocytes versus in vitro fertilization in women with a high antral follicle count.
    Ho VNA; Braam SC; Pham TD; Mol BW; Vuong LN
    Hum Reprod; 2019 Jun; 34(6):1055-1064. PubMed ID: 31111879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol.
    Fatemi HM; Popovic-Todorovic B; Humaidan P; Kol S; Banker M; Devroey P; García-Velasco JA
    Fertil Steril; 2014 Apr; 101(4):1008-11. PubMed ID: 24534283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication.
    Itskovitz-Eldor J; Kol S; Mannaerts B
    Hum Reprod; 2000 Sep; 15(9):1965-8. PubMed ID: 10966996
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current Medical Strategies in the Prevention of Ovarian Hyperstimulation Syndrome.
    Kasum M; Orešković S; Franulić D; Čehić E; Lila A; Vujić G; Grgić F
    Acta Clin Croat; 2017 Mar; 56(1):133-142. PubMed ID: 29120551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Second Dose of GnRHa in Combination with Luteal GnRH Antagonist May Eliminate Ovarian Hyperstimulation Syndrome in Women with ≥30 Follicles Measuring ≥11 mm in Diameter on Trigger Day and/or Pre-trigger Peak Estradiol Exceeding 10 000 pg/mL.
    Deng L; Li XL; Ye DS; Blockeel C; Zhou XY; Chen SL; Chen X
    Curr Med Sci; 2019 Apr; 39(2):278-284. PubMed ID: 31016522
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos.
    Endo T; Honnma H; Hayashi T; Chida M; Yamazaki K; Kitajima Y; Azumaguchi A; Kamiya H; Kudo R
    Hum Reprod; 2002 Oct; 17(10):2548-51. PubMed ID: 12351526
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
    Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
    Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in "freeze-all" approach.
    Fernández-Sánchez M; Fatemi H; García-Velasco JA; Heiser PW; Daftary GS; Mannaerts B
    Gynecol Endocrinol; 2023 Dec; 39(1):2205952. PubMed ID: 37156263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 53. GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial.
    Fouda UM; Sayed AM; Elshaer HS; Hammad BE; Shaban MM; Elsetohy KA; Youssef MA
    J Ovarian Res; 2016 May; 9(1):29. PubMed ID: 27184139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
    Atkinson P; Koch J; Ledger WL
    Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Luteal phase support with GnRH agonist does not eliminate the risk for ovarian hyperstimulation syndrome.
    Friedler S; Grin L
    Gynecol Endocrinol; 2019 May; 35(5):368-369. PubMed ID: 30614333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization.
    Kaye L; Griffin D; Thorne J; Neuber E; Nulsen J; Benadiva C; Engmann L
    Fertil Steril; 2019 Sep; 112(3):534-544. PubMed ID: 31227286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases.
    Gurbuz AS; Gode F; Ozcimen N; Isik AZ
    Reprod Biomed Online; 2014 Nov; 29(5):541-4. PubMed ID: 25246114
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
    Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
    J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of gonadotrophin-releasing hormone agonists to trigger ovulation.
    Tay CC
    Hum Fertil (Camb); 2002 Feb; 5(1):G35-7; discussion G38-9, G41-8. PubMed ID: 11939159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.